FDA Panel To Take Second Look After J&J Plugged Holes In Xarelto ATLAS Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Broader issue of missing data in clinical trials could see further discussion as FDA’s Cardiovascular and Renal Advisory Committee will relook at Xarelto’s acute coronary syndrome indication Jan. 16, now that J&J has tried to address the missing data that befuddled the committee on the first go-round.
You may also be interested in...
J&J To Persevere In ACS After Another “Complete Response” For Xarelto
J&J says it remains confident about getting expanded approval for Xarelto after receiving a “complete response” letter from FDA for reducing risk of stent thrombosis in patients with acute coronary syndrome.
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
The agency’s decision not to approve the Factor Xa inhibitor for treating acute coronary syndrome patients follows a negative recommendation by an FDA advisory committee, which was concerned about missing data in the pivotal ATLAS trial. FDA may be seeking more clarity on the issue of missing vital status follow-up for patients who withdrew consent in that study.
FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms
Despite the agency’s decision to limit discussion about missing data to the ATLAS pivotal trial of rivaroxaban, Cardio-Renal advisory committee members suggested reforms that sponsors should consider to prevent the kinds of problems seen in ATLAS.